- The disease
- Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, in which malignant cells form in the ducts of the pancreas. It is typically diagnosed at an advanced stage, when surgical removal is not possible. Standard first-line treatment for advanced PDAC has for many years combined chemotherapy agents, including gemcitabine and nab-paclitaxel (a form of the drug paclitaxel bound to albumin nanoparticles). Outcomes remain poor across treatment lines.
- What the asset is trying to do
- AMP945 is a kinase inhibitor, meaning it is designed to block the activity of one or more specific enzymes (kinases) that relay signals inside cells. The precise kinase target of AMP945 is not disclosed in the available data. In the ACCENT trial, AMP945 is being tested in combination with the standard chemotherapy backbone of nab-paclitaxel and gemcitabine, on the hypothesis that inhibiting the target kinase alongside chemotherapy may add benefit over chemotherapy alone.
- What the trial is measuring, and why it matters
- The ACCENT trial (NCT05355298) is measuring the safety, tolerability, and preliminary efficacy of AMP945 combined with nab-paclitaxel and gemcitabine in PDAC patients (per ClinicalTrials.gov NCT05355298). The Phase 1 portion establishes the recommended Phase 2 dose (RP2D) through ascending dose cohorts; the Phase 2 portion then tests AMP945 at the RP2D (per ClinicalTrials.gov NCT05355298). Mature data from the trial were presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026 (per ASX announcement, 21 April 2026).
- Efficacy benchmarks in this setting
- In advanced PDAC treated with first-line nab-paclitaxel plus gemcitabine, the pivotal MPACT trial reported an objective response rate (ORR) of 23% and median overall survival (OS) of 8.5 months, compared with 7.0 months for gemcitabine alone (Von Hoff et al, New England Journal of Medicine, 2013). FOLFIRINOX (a four-drug chemotherapy regimen) achieved a median OS of 11.1 months versus 6.8 months for gemcitabine in the same setting in the PRODIGE 4/ACCORD 11 trial (Conroy et al, New England Journal of Medicine, 2011). Early-stage, non-randomised figures from the ACCENT trial are not statistically comparable to these controlled trial benchmarks.
- Commercial context
- No targeted therapy specifically directed at the kinase class inhibited by AMP945 is currently approved for PDAC, based on publicly available regulatory information. The combination chemotherapy regimens nab-paclitaxel plus gemcitabine and FOLFIRINOX represent the established first-line standard of care for advanced PDAC. AMP945 appears to be Amplia Therapeutics' (ASX: ATX) lead clinical-stage asset based on available company disclosures; .